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ABSTRACT 1 
Introduction  2 
The beneficial effect of dietary omega-3 supplementation in younger adults, or older people 3 
with acute or chronic disease is established. Knowledge is now needed about the effect in 4 
medically stable older people. The objective of this study is to examine and assess the 5 
evidence for a role of dietary omega-3 polyunsaturated fatty acid (PUFA) supplementation 6 
in older adults on (1) muscle mass and muscle strength (2) inflammatory biomarkers and (3) 7 
physical activity. 8 
Methods and analysis 9 
A systematic review and data synthesis will be conducted of randomised controlled trials in 10 
older people not recruited for any given disease diagnosis. Placebo controlled studies 11 
reporting interventions involving dietary supplementation of omega-3 PUFAs, 12 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) will be included. Outcomes 13 
must include changes from baseline to last available follow-up for one or more of the 14 
following: muscle mass; inflammatory biomarkers; physical activity; walking speed; weight 15 
change; hand grip strength or muscle strength. Once the search strategy has been carried 16 
out, two independent researchers will assess relevant papers for eligibility. Articles up until 17 
31st December 2017 in any language will be included. We will provide a narrative synthesis 18 
of the findings from the included studies. Studies will be grouped for meta-analysis 19 
according to the outcome(s) provided. Where studies have used the same type of 20 
intervention, with the same outcome measure, we will pool the results using a random-21 
effects meta-analysis, with standardised mean differences for continuous outcomes and risk 22 
ratios for binary outcomes, and calculate 95% confidence intervals and two-sided P values 23 
for each outcome. 24 
Ethics and dissemination 25 
No research ethics approval is required for this systematic review, as no confidential patient 26 
data will be used. The results of this systematic review will be disseminated through 27 
publication in an open access peer-reviewed journal and through conference presentations. 28 
PROSPERO registration number: CRD42017080240 29 
 30 
 31 
 32 
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STRENGTHS AND LIMITATIONS OF THIS STUDY 1 
• This will be the first study to systematically examine the effect of dietary omega-3 2 
fatty acid supplementation on frailty related phenotypes inolder adults not selected 3 
for specific chronic or acute conditions.  4 
• An important strength of the study is the focus on both functional (walking speed, 5 
grip strength, get up and go) and inflammatory outcomes (cytokine level) outcomes 6 
which will allow to put in context the effect size  and direction of effect of omega-3 7 
supplementation and to prioritise outcomes for future RCTs. 8 
• Results will also help to inform future guidelines on dietary supplementation for 9 
older adults. 10 
• Limitations may include issues of poor reporting affecting risk of bias assessment and 11 
confidence in results. 12 
 13 
INTRODUCTION 14 
 15 
According to the United Nations, the number of people aged over 60 will double globally 16 
from 962 million in 2017 to 2.1 billion in 2050.1 In Europe, the proportion of the population 17 
aged over 60 is projected to reach 35% by 2050.1 It is, therefore, a global priority to ensure 18 
that this ageing population remains independent. A key element of maintaining 19 
independence in older adults is the preservation of mobility along with muscle mass and 20 
strength.  21 
 22 
Muscle mass decline is one of the hallmarks of ageing and, from age 40 muscle mass begins 23 
to decrease, with an annual decline in functional capacity of up to 3% per year after age 60.2 24 
A key gerontological concept linked to musculoskeletal ageing is frailty.3 The commonly 25 
acknowledged characteristics include unintentional weight loss, self-reported exhaustion, 26 
weakness (grip strength), slow walking speed, and low physical activity.4 This complex 27 
phenomenon is highly correlated with loss of mobility along with progressive loss of skeletal 28 
muscle strength (dynapenia), mass and function (sarcopenia)5 and results in a reduced 29 
quality of life and is a major public health concern.6 30 
 31 
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The prevalence of frailty also increases with age, and along with sarcopenia is associated 1 
with serious adverse outcomes, including falls, hospitalisation and mortality.7 There is 2 
consensus of an inflammatory contribution to frailty. Striking differences in the levels of pro-3 
inflammatory cytokines between frail and non-frail elderly have been reported,8 and predict 4 
higher mortality.9 5 
A role for nutritional determinants of frailty has been proposed10 and a number of lifestyle 6 
interventions have been investigated with regards to frailty, including exercise and 7 
increased protein intake.11 8 
 9 
Recent work has also begun to investigate such interventions to prevent or diminish muscle 10 
loss in medical settings, including the supplementation of leucine12, vitamin D13 and fish-11 
derived polyunsaturated omega 3 fatty acids (PUFA), eicosapentaenoic acid (EPA) and 12 
docosahexaenoic acid (DHA). Studies carried out in a variety of populations including cancer 13 
patients,14 patients with end-stage renal disease,15 chronic obstructive pulmonary disease16 14 
and rheumatoid arthritis17 have shown that dietary PUFAs have a beneficial effect on 15 
skeletal muscle mass and strength. 16 
 17 
Dietary supplementation of omega-3 PUFAs is of particular interest in the context of frailty, 18 
given its well-known anti-inflammatory role and the importance of inflammation in the 19 
development of ageing.
18
 20 
 21 
Omega-3 reduces inflammation in conditions including Duchenne muscular dystrophy,
19
 22 
Crohn’s disease,
20
 non-alcoholic fatty liver disease,
21
 cardiovascular disease
22
 as well as 23 
many cancers.
14 23-25
 These studies are of particular interest, as increased levels of 24 
inflammatory biomarkers such as interleukin-6 (IL-6), tumour necrosis factor-alpha (TNFα) 25 
and C reactive protein (CRP) have all been linked with both frailty and sarcopenia in older 26 
adults.
26-28
 Long chain PUFAs have been suggested to interact with antioxidants and improve 27 
inflammatory responses to positively impact on physical performance.
29
  Part of the 28 
mechanism may involve the effect of omega-3 on musculoskeletal pain; a pain reduction 29 
would be conducive to more physical activity. 
30
 More generally, omega-3 supplementation 30 
may act directly on skeletal muscle and improve protein metabolism hence having an 31 
Page 4 of 18
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
influence on physical performance. 31 32 A more pro-inflammatory diet has also been linked 1 
with a higher incidence of frailty.33 2 
 3 
A recent review by Ticinesi et al.18 summarised the analysis of omega-3 PUFAs on 4 
inflammation in older individuals in both cross-sectional and randomized controlled trials. 5 
However, we are not aware of any systematic reviews or meta-analyses focussing 6 
specifically on omega-3 fatty acid supplementation on frailty phenotypes in older adults not 7 
selected for any specific chronic or acute conditions. We propose to conduct a systematic 8 
review and meta-analysis to examine the effect of dietary omega-3 supplementation in 9 
older people not recruited for any given disease diagnosis. The outcomes that will be 10 
investigated are inflammatory biomarkers;  muscle mass; physical activity; walking speed; 11 
weight change; hand grip strength or muscle strength, as well as biases in the included 12 
studies.  13 
 14 
METHODS AND ANALYSIS 15 
Registration 16 
This protocol has been registered with PROSPERO (registration number CRD4201708024034) 17 
and reported in accordance with Preferred Reporting Items for Systematic Reviews and 18 
Meta-Analyses (PRISMA)
35
 and PRISMA-Protocol 
36 37
 guidelines. 19 
 20 
Study selection criteria 21 
Interventions and population 22 
Studies reporting results of interventions involving dietary supplementation of omega-3 23 
PUFAs will be included. Dietary supplementation will be defined as daily ingestion of 24 
capsules containing EPA and DHA or through an EPA and DHA enriched diet. The 25 
comparator will be placebo-controlled groups. Participants will include community-dwelling, 26 
persons, of either sex, classified by the study authors as postmenopausal or older people 27 
with the majority of participants over 60 years of age. To ensure the focus of the review is 28 
on older people not recruited for any given disease diagnosis, exclusions will be studies 29 
where participants were selected because they had a cancer or other chronic disease 30 
diagnosis. Participants who currently consumed a high fish diet or use fish oil supplements 31 
will also be excluded. 32 
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 1 
Outcomes 2 
Outcomes must include changes from baseline to last available follow-up for one or more of 3 
the following: muscle mass; inflammatory biomarkers; physical activity; walking speed; 4 
weight change; hand grip strength or muscle strength. Any adverse effects will also be 5 
summarised. Studies will be grouped for meta-analysis according to the outcome(s) 6 
provided. 7 
Study designs 8 
Randomised controlled trials (RCTs) will be included. 9 
 10 
Other 11 
Articles up until 31st December 2017 in any language will be included. 12 
 13 
Exclusion criteria 14 
Studies will be excluded for the following reasons: (1) study population was specifically 15 
focused on participants diagnosed and being treated for a pre-existing medical condition 16 
(e.g. cancer, kidney disease, liver disease, diabetes mellitus, cardiovascular disease); or (2) 17 
letters to the editor, meta-analyses, case reports and reviews. 18 
 19 
Search strategy 20 
MEDLINE (OVID) from 1946, the Cochrane Register of Controlled Trials (CENTRAL) from 21 
1940, EMBASE from 1946, Cumulative Index to Nursing and Allied Health Literature 22 
(CINAHL) from 1937, Allied and Complementary Medicine Database (AMED) and Web of 23 
Science will be searched for relevant trials. The search strategy for Medline has been 24 
developed in consultation with a subject-specific librarian and will be adapted for use in 25 
other databases. Search terms are informed by Cochrane Handbook
38
 and other systematic 26 
reviews investigating PUFA dietary supplementation, sarcopenia and/or frailty. 27 
 28 
The full search strategy can be found in the supplementary file 1. Example of searches that 29 
will be used can be seen in supplementary file 2, Box 1 MEDLINE (OVID) Advanced Search 30 
Example. Syntax (truncation, wildcards and quotation marks) and operators will be 31 
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amended according to the specific databases. Initial search results will be uploaded to 1 
EndNote X7 (Thomas Reuters) prior to the review of titles and abstracts.  2 
Data extraction  3 
Initial title and abstract review will be conducted by the first author (JS). Duplicates and 4 
articles clearly not meeting the selection criteria will be removed. The reference lists from 5 
identified letters to the editor, meta-analyses, case reports and reviews will be scanned to 6 
identify further trials. Two-independent researchers (JS and AMV) will then read the full text 7 
of remaining relevant papers for eligibility. In cases where the two researchers cannot agree 8 
on eligibility, a third researcher will mediate. Authors of grey literature will be contacted 9 
when conference abstracts and proceedings are found. A PRISMA flowchart will be used to 10 
provide transparency of the number of papers included or excluded at each stage. Two-11 
independent researchers (JS and AMV) will extract the data. The data extracted from the 12 
studies (if available) will include (1) authors; (2) publication year; (3) country; (4) funding; (5) 13 
setting; (6) study design; (7) sample size; (8) dosage; (9) duration of monitoring or 14 
intervention; (10) withdrawals; (11) mean age; (12) gender; (13) muscle mass; (14) physical 15 
activity; (15) muscle strength; (16) walking speed; (17) weight; (18) handgrip strength and 16 
(19) biomarkers; 17 
 18 
Risk of bias assessment 19 
Reporting bias will be assessed by plotting the inverse of the SEs of the effect estimates 20 
using funnel plots where meta-analysis includes more than 10 trials and will be assessed 21 
visually for asymmetry
39
 and with the Egger's regression test for continuous variables.
40
 22 
Analysis will be conducted on Review Manager Software.
41
 23 
 24 
JS and AMV will independently assess the risk of study bias using the Cochrane 25 
Collaboration’s tool for assessing risk of bias in randomised trials.
42
 The Cochrane risk of bias 26 
tool for RCT’s consists of the following seven items: (1) random sequence generation; (2) 27 
allocation concealment; (3) blinding of participants and personnel; (4) blinding of outcome 28 
assessment; (5) incomplete outcome data; (6) selective reporting; (7) other sources of bias. 29 
Questions are rated as having a high, low or unclear level of bias across the seven domains. 30 
Page 7 of 18
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
 1 
Strength of evidence evaluation 2 
Strength of evidence will be assessed by GRADE system,43 i.e. quality of evidence for each 3 
outcome, relative importance of outcomes and overall quality of evidence. 4 
 5 
Data management and statistical analysis 6 
Data obtained through data extraction will be entered into Excel. Outcomes will be 7 
imported into RevMan41 for meta-analysis. Data extracted must be presented as mean and 8 
standard deviation, not ranges, and will not be estimated from graphs or figures. Authors 9 
will be contacted if mean and standard deviation values are not presented. 10 
 11 
We will create a table describing study characteristics and major outcomes. We will provide 12 
a narrative synthesis of the findings from the included studies, structured around the type 13 
and content of intervention (i.e. diet alone or in combination with training), target 14 
population characteristics (i.e. sex, age, body mass index (BMI)), type of outcome (i.e. 15 
muscle strength; physical performance; muscle mass; cognitive function). We will provide 16 
summaries of intervention effects for each study by calculating risk ratios (for dichotomous 17 
outcomes) or standardised mean differences (for continuous outcomes). 18 
 19 
We anticipate that there will be limited scope for meta-analysis because of the range of 20 
different outcomes measured across the small number of existing trials. However, where 21 
studies have used the same type of intervention, with the same outcome measure, we will 22 
pool the results using a random-effects meta-analysis, with standardised mean differences 23 
for continuous outcomes and risk ratios for binary outcomes, and calculate 95% confidence 24 
intervals and two-sided P values for each outcome. In studies where the effects of clustering 25 
have not been taken into account, we will adjust the standard deviations for the design 26 
effect. Heterogeneity between the studies in effect measures will be assessed using the I² 27 
statistic.
44
 We will consider an I² value greater than 50% indicative of moderate 28 
heterogeneity or 75% high heterogeneity.
45
  29 
 30 
We will conduct sensitivity analyses based on study quality. We will use stratified meta-31 
analyses to explore heterogeneity in effect estimates according to participant characteristics 32 
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(e.g. sex, age, BMI), location (e.g. hospital or community setting), intervention components 1 
(e.g. diet alone or in combination with training), the logistics of intervention provision. 2 
 3 
Outcomes and prioritisation. 4 
The primary outcomes will include recognised frailty criteria of physical activity levels; 5 
walking speed; hand-grip strength or muscle strength; and weight4 along with changes in 6 
muscle mass and circulating levels of the pro-inflammatory markers CRP, IL-6 and TNF-α. 7 
Other outcomes will be analysed if available including body fat mass. 8 
Patient and Public Involvement 9 
The research question was developed following a patient involvement event in May 2017 10 
with members from Arthritis Research UK Pain Centre and National Institute for Health 11 
Research Biomedical Research Centre Musculoskeletal PPI group. Members of the PPI group 12 
informed the authors that they already take a number of pharmaceutical treatments and 13 
they have a preference for learning more about possible lifestyle interventions, such as 14 
dietary modification where they can take control of their only health and well-being. 15 
Patients were not involved in the design of this systematic review.  16 
 17 
ETHICS AND DISSEMINATION 18 
No research ethics approval is required for this systematic review, as no confidential patient 19 
data will be used. It is intended that the results of this systematic review will be 20 
disseminated through publication in an open access peer-reviewed journal and through 21 
conference presentations. All amendments to the protocol will be documented, dated and 22 
reported in the PROSPERO trial registry. 23 
 24 
DISCUSSION 25 
This systematic review will utilise rigorous methodology, to identify and examine studies 26 
reporting the outcome of omega-3 supplementation on frailty related traits on ageing 27 
groups not selected for specific chronic or acute conditions, including both inflammatory 28 
biomarkers and functional measures. No systematic review has previously addressed this 29 
objective although numerous published reviews have focused on ageing populations 30 
suffering from chronic or acute conditions. For example, there is evidence of beneficial 31 
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effects of omega-3 supplementation for individuals undergoing chemotherapy or 1 
radiotherapy for cancer46 for risk reduction in individuals with established atherosclerotic 2 
cardiovascular disease47 and some beneficial effect on liver function in individuals with non-3 
alcoholic fatty liver disease48 among others. 4 
 5 
Although risk of bias and overall level of evidence may limit analyses and confidence in this 6 
review's conclusions, this synthesis will provide a better understanding of the effect of 7 
omega-3 supplementation in preventing systemic inflammation and functional decline in 8 
the elderly population.   9 
 10 
Implications of results 11 
This review will provide the first rigorous summary of effect of omega-3 supplementation 12 
across all published randomized controlled trial studies of elderly individuals not selected 13 
for chronic or acute conditions. The findings will inform our understanding of the value of 14 
this popular nutritional supplement in preventing frailty-related outcomes. 15 
 16 
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Supplementary File: Search Strategy 
 
Study population terms: 
 Population, target condition and outcomes: Older people and frailty  
(‘aged’ OR ‘old’ OR ‘age-old’ OR ‘elder’ OR ‘senior’ OR ‘functionally impaired’ OR ‘frail’ 
OR ‘exp frail elderly’ OR ‘ageing’ OR ‘aging’ OR ‘post-menopausal’  OR ‘postmenopaus*’) 
OR ‘sarcopenia’ OR ‘hand strength’ OR ‘weight’ OR ‘walking speed’ OR ‘muscle strength’ 
OR ‘physical activity’). 
AND 
 Intervention: Omega-3 polyunsaturated fatty acid 
(‘Eicosapentaenoic Acid’ OR ‘Docosahexaenoic Acid’ OR ‘Fatty Acids, Omega-3’ OR ‘Fatty 
Acids, Unsaturated’ OR ‘omega-3 fatty acid*’ OR ‘polyunsaturated fatty acid*’ OR ‘EPA’ 
OR ‘DHA’ OR ‘PUFA’ OR ‘omega-3’). 
AND 
 Methodology: Randomised Control Trials 
(‘randomised controlled trial’ OR ‘controlled clinical trial’ OR ‘randomised’ OR ‘placebo’ 
OR ‘clinical trials as topic’ OR ‘randomly’ OR ’trial’) 
AND 
 Humans: NOT ‘animals/NOT humans’ 
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Box 1. Example of an advanced search strategy—MEDLINE OvidSP 1946 to 30th November 2017 
Stages and detail of search strategy 
1 aged.mp. or Aged/ 
2 old.mp.  
3 age-old.mp. 
4 elder.mp.  
5 senior.mp.  
6 Functionally-Impaired.mp. 
7 frail.mp.  
8 exp Frail Elderly/ 
9 ageing.mp. 
10 Aging/ or aging.mp. 
11 post-menopausal.mp. 
12 postmenopaus*.mp. 
13 sarcopenia.mp. or Sarcopenia/ 
14 hand strength/ or handgrip strength.mp. 
15 weight.mp. 
16 walking speed.mp. or Walking Speed/ 
17 muscle strength.mp. or Muscle Strength/ 
18 physical activity.mp. or Exercise/ 
19 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 
20 Eicosapentaenoic Acid.mp. or Eicosapentaenoic Acid/ 
21 Docosahexaenoic Acid.mp. or Docosahexaenoic Acids/ 
22 Fatty Acids, Omega-3.mp. or Fatty Acids, Omega-3/ 
23 Fatty Acids, Unsaturated.mp. or Fatty Acids, Unsaturated/ 
24 omega-3 fatty acid*.mp. 
25 polyunsaturated fatty acid*.mp. 
26 EPA.mp. 
27 DHA.mp. 
28 PUFA.mp. 
29 omega-3.mp. 
30 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 
31 Randomi?ed controlled trial.mp. 
32 Controlled clinical trial.mp 
33 Randomised.mp 
34 Placebo.mp.  
35 Phase 4 clinical trial.mp. 
36 Single Blind Procedure.mp. 
37 Double Blind Procedure.mp. 
38 Crossover Procedure.mp. 
39 Clinical trials.mp.  
40 Randomly.mp.  
41 Trial.mp. 
42 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42  
43 19 and 30 and 42  
44 exp animals/ not humans.sh. 
45 43 not 44 
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PRISMA-P 2015 Checklist  
Section/topic # Checklist item 
Information reported Line 
number(s) Yes No 
ADMINISTRATIVE INFORMATION   
Title  
  Identification  1a Identify the report as a protocol of a systematic review   P1, 2 
  Update  1b If the protocol is for an update of a previous systematic review, identify as such   NA 
Registration  2 
If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the 
Abstract 
  P2, 29 
Authors  
  Contact  3a 
Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical 
mailing address of corresponding author 
  P1, 4-22 
  Contributions  3b Describe contributions of protocol authors and identify the guarantor of the review   P12, 31-35 
Amendments  4 
If the protocol represents an amendment of a previously completed or published protocol, identify 
as such and list changes; otherwise, state plan for documenting important protocol amendments 
  NA 
Support  
  Sources  5a Indicate sources of financial or other support for the review   P12, 40 
  Sponsor  5b Provide name for the review funder and/or sponsor   P12, 40 
  Role of 
sponsor/funder  
5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol   
NA 
INTRODUCTION  
Rationale  6 Describe the rationale for the review in the context of what is already known   P3-5, 11-6 
Objectives  7 
Provide an explicit statement of the question(s) the review will address with reference to 
participants, interventions, comparators, and outcomes (PICO) 
 
  P2, 10-16   
METHODS  
Eligibility criteria  8 Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report   P5-6, 14-11 
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Section/topic # Checklist item 
Information reported Line 
number(s) Yes No 
characteristics (e.g., years considered, language, publication status) to be used as criteria for 
eligibility for the review 
Information sources  9 
Describe all intended information sources (e.g., electronic databases, contact with study authors, 
trial registers, or other grey literature sources) with planned dates of coverage 
  P6, 5 & 13-20 
P7, 3-4 
Search strategy  10 
Present draft of search strategy to be used for at least one electronic database, including planned 
limits, such that it could be repeated 
  Supplementary 
file 
STUDY RECORDS  
  Data management  11a Describe the mechanism(s) that will be used to manage records and data throughout the review 
  P6, 25 
P7-8, 30-32 
P8, 4  
  Selection process  11b 
State the process that will be used for selecting studies (e.g., two independent reviewers) through 
each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis) 
  P6-7, 28-3 
  Data collection 
process  
11c 
Describe planned method of extracting data from reports (e.g., piloting forms, done independently, 
in duplicate), any processes for obtaining and confirming data from investigators 
  P7, 5-11 
P7, 3-4 
Data items  12 
List and define all variables for which data will be sought (e.g., PICO items, funding sources), any 
pre-planned data assumptions and simplifications 
  P7, 7-11 
Outcomes and 
prioritization  
13 
List and define all outcomes for which data will be sought, including prioritization of main and 
additional outcomes, with rationale 
  P8, 29-32 
Risk of bias in 
individual studies  
14 
Describe anticipated methods for assessing risk of bias of individual studies, including whether this 
will be done at the outcome or study level, or both; state how this information will be used in data 
synthesis 
  P7, 14-24 
DATA 
Synthesis  
15a Describe criteria under which study data will be quantitatively synthesized   P8, 13-14 
15b 
If data are appropriate for quantitative synthesis, describe planned summary measures, methods of 
handling data, and methods of combining data from studies, including any planned exploration of 
consistency (e.g., I 
2
, Kendall’s tau) 
  P8, 15-21 
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Section/topic # Checklist item 
Information reported Line 
number(s) Yes No 
15c 
Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression) 
  P8, 23-26 
15d If quantitative synthesis is not appropriate, describe the type of summary planned   P8, 4-8 
Meta-bias(es)  16 
Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective 
reporting within studies) 
  P7, 14-24 
Confidence in 
cumulative evidence  
17 Describe how the strength of the body of evidence will be assessed (e.g., GRADE)          
P7, 27-28 
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